This phase I/II study is evaluating how safe and effective combining three targeted and immuno-therapies (nivolumab, relatilmab + bevacizumab) is, compared to the combination of two therapies (nivolumab + bevacizumab), in people with untreated, advanced or metastatic liver cancer.
This trial is treating patients with liver cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination With Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
Bristol-Myers Squibb (BMS)
Eligible participants will be randomly allocated to either the Experimental Arm or the Placebo Comparator Arm. In the Experimental Arm, participants will receive Relatlimab + Nivolumab + Bevacizumab. In the Placebo Comparator Arm, participants will receive Placebo + Nivolumab + Bevacizumab.
Recruiting Hospitals Read More